Holen Sie sich die Stockscreener-App
52.02
2.42%
-1.37
Schlusskurs vom Vortag:
$53.39
Offen:
$54.31
24-Stunden-Volumen:
3.87M
Relative Volume:
0.33
Marktkapitalisierung:
$20.56B
Einnahmen:
$1.94B
Nettoeinkommen (Verlust:
$-2.82B
KGV:
-7.1636
EPS:
-7.2617
Netto-Cashflow:
$-2.08B
1W Leistung:
-0.80%
1M Leistung:
+23.37%
6M Leistung:
+121.61%
1J Leistung:
+51.90%
1-Tages-Spanne:
$51.77
$55.09
1-Wochen-Bereich:
$51.77
$57.88
52-Wochen-Spanne:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
52.06 | 21.09B | 1.94B | -2.82B | -2.08B | -7.2617 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.21 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.69 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.24 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.56 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.97 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
3 Healthcare Stocks to Avoid in 2026: Analysis of UnderperformersNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Moderna Valuation Questioned As mRNA Guidance And Flu Review Shift - simplywall.st
Moderna’s Spikevax update: What US patients really need to know now - AD HOC NEWS
Moderna, Inc. $MRNA Position Increased by Theleme Partners LLP - MarketBeat
An Erratic FDA Is a Threat to Innovation - Bloomberg.com
Moderna operates through several specialized therapeutic “pillars”: - WhatJobs
Moderna (MRNA) and BioNTech (BNTX) Shares Rise on Advisory Rever - GuruFocus
Moderna Settles Patent Litigation with Arbutus et al. - JD Supra
Is It Too Early To Reassess Moderna (MRNA) After Its Strong 2024 Share Price Rally? - simplywall.st
Jefferies Financial Group Reduces Moderna Stake - National Today
Jefferies Financial Group Inc. Sells 32,310 Shares of Moderna, Inc. $MRNA - MarketBeat
US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports - Reuters
Moderna: Pipeline Hope Won't Pay The Bills (NASDAQ:MRNA) - Seeking Alpha
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Moderna Stock Hits Day High with 6.13% Surge, Outperforming S&P 500 - Markets Mojo
BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture - Benzinga
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks - Intellectia AI
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Lyme Disease Vaccine Market Is Booming So Rapidly | Valneva SE • Pfizer Inc. • Moderna Inc - openPR.com
Quantbot Technologies LP Sells 34,481 Shares of Moderna, Inc. $MRNA - MarketBeat
MRNA Stock Quote Price and Forecast - CNN
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Moderna surges after hours on patent settlement with Arbutus and Genevant - MSN
Is Moderna (MRNA) Pricing Too High After Its Recent 70% Year To Date Rally - Yahoo Finance
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook - Yahoo Finance
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - Lubbock Avalanche-Journal
Is Moderna Inc. stock attractive after correction2026 Major Catalysts & Long-Term Growth Stock Strategies - Naître et grandir
Aug Highlights: Why Moderna Inc. stock appeals to analystsTrade Entry Report & Weekly Stock Performance Updates - Naître et grandir
Moderna Stock (MRNA) Opinions on FDA Vaccines Chief Departure | MRNA Stock News - Quiver Quantitative
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Moderna (MRNA) Chief Legal Officer logs RSU conversion and tax share disposition - Stock Titan
Market Watch Rx: IQVIA Joins Top Gainers - Pharmaceutical Executive
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 7.6%Here's What Happened - MarketBeat
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug - RTTNews
These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next - 24/7 Wall St.
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
Best Biotech Stocks To Add to Your WatchlistMarch 5th - MarketBeat
Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit - Pharmaceutical Technology
Moderna reaches agreement in COVID-19 intellectural property dispute - Delaware Business Now
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement - FinancialContent
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - Stock Traders Daily
Moderna Resolves $950M Patent Battle Over COVID-19 Vaccine Tech—Find Out How It Impacts the Industry - Investing News Network
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era - FinancialContent
Moderna Stock Surges 16% Following Global Patent Litigation Settlement - TIKR.com
Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn - 24/7 Wall St.
Moderna, Inc. Opens with 7.53% Gain, Outperforming S&P 500's Decline - Markets Mojo
Moderna (MRNA) Reaches Settlement Agreement with Arbutus Biophar - GuruFocus
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com Nigeria
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):